Product manufacturing uses a wide range of processing centers

A 20 mm crimp finish, a 13 mm butyl stopper, and an aluminum seal with a 3.0 mm flip-off cap: three components, one bill of materials, and a single line that says “manufacturer: TBD” on the specification sheet. That line is where OEM versus private label for vial closures gets decided, and it is almost never decided by the person who wrote the spec. The purchasing group fills it in later, the brand prints on the carton, and six months down the road a fill line starts rejecting vials at 1.8% on a headspace integrity check that used to run at 0.2%. The factory did not change. The label did. The tooling, the recipe, and the liability all moved, and nobody wrote it down.

The OEM vs private label vial closures difference is not a marketing distinction. It is a question of who owns the mold, who holds the compound formulation, and who signs the certificate of analysis. When the brand on the box changes but the injection molding press does not, those three things can stay put or move, and the answer determines what you can audit, what you can change, and what you are stuck with when a lot drifts.

Start with the steel. A 13 mm bromobutyl stopper is molded in a multi-cavity tool, often 64 to 128 cavities for a high-volume format, and that tool is a capital asset worth somewhere between $80,000 and $400,000 depending on cavity count, finish requirements, and whether it runs on a compression press or an injection molding machine. Whoever owns that tool controls the part geometry for its service life.

In a true OEM arrangement, the brand house (the company whose name is on the vial closure) commissions the tool, holds title to it, and specifies the cavity layout, the gate location, the radii, and the surface finish. The contract manufacturer runs the tool but does not own it. If the molder’s press goes down or the relationship sours, the tool can be pulled and moved. That portability is the whole point of OEM tooling ownership: the brand can requalify a second source without re-cutting steel.

In a private label arrangement, the tooling usually belongs to the factory. The brand buys finished goods off an existing tool, applies its label, and sells them. That is cheaper and faster, and it is fine right up to the moment the factory decides to change something. A cavity gets reworked. A gate gets moved to improve cycle time. A different compound lot arrives with a slightly different cure package. None of that requires the brand’s consent, because the brand does not own the asset that produces the part.

What to ask about the tool

• Who holds title to the mold, and is that stated in writing?
• How many cavities, and is the cavity number stamped or laser-marked on the part or the runner?
• When was the tool last serviced, and what was the dimensional drift on the sealing land?
• If the tool is pulled, can it run on a second press without re-qualification?

That last question is the one that separates a real OEM relationship from a label swap. If the answer is “no, the tool only fits our press,” you have a private label part with an OEM-sounding name.

The recipe is the part you cannot see on a drawing

A stopper drawing shows a flange diameter, a plug diameter, a plug length, and a durometer. It does not show the compound. A 13 mm bromobutyl formulation might contain 40 to 60 parts per hundred rubber of filler, a cure system, an accelerator, an antioxidant, and a small amount of process aid. Those ratios control extractables, coring resistance, compression set, and the way the part behaves after 20 punctures with a 22-gauge needle.

In OEM work, the compound formulation is often proprietary to the brand and locked to a specification the molder must meet. The brand can require a specific extractables profile, a specific volatile profile by headspace GC, and a specific compression set at 121°C for 22 hours. The molder’s job is to hit those numbers, and the brand can audit the batch records that prove it.

In private label work, the compound is usually the factory’s standard grade. It meets a general pharmacopeial requirement (often USP Class VI or the relevant ISO 10993-5 cytotoxicity screen) and it is consistent within the factory’s own tolerance. What it is not is a formulation you specified. If your method requires low extractables for a trace-level assay, or a compound that resists coring across a 100-injection sequence, the factory’s standard grade may or may not deliver, and you will not know until you test it.

This is where the “material grade” question gets real. Two closures can both be labeled “bromobutyl” and differ by a factor of two in extractable zinc or in the number of visible particles shed per puncture. The label does not tell you. The compound specification sheet does, and in a private label deal you often cannot get one because the factory treats it as confidential. I have watched a procurement team accept a private label stopper on the strength of a USP Class VI letter, only to find 0.8 µg/mL of an unidentified extractable at 40°C after 30 days, which was above their own internal limit and invisible on the vendor’s paperwork.

The certificate of analysis is the real dividing line

Here is the practical test I use. Ask for the last 24 months of lot release data, then ask who signed it. In an OEM arrangement, the COA is issued against a specification the brand wrote, and the brand can be held to it. In a private label arrangement, the COA is issued by the factory against the factory’s own specification, and the brand is a reseller. If a lot fails, the brand’s recourse is a complaint to the factory. Your recourse is a complaint to the brand. That is one extra link in the chain, and it is the link that usually breaks.

The traceability chain matters here. A closure lot should trace back to a compound lot, a mold cavity, a press cycle, and a cure record. In OEM work, the brand typically holds that chain and can produce it. In private label work, the chain stops at the factory’s door, and the brand may only have a certificate that says “conforms.” For regulated fill-finish operations, that difference is not cosmetic. It is the difference between a defensible deviation report and a shrug.

What each model actually gives you

Read that table as a decision aid, not a ranking. Private label is the right answer for a lot of operations. The point is to know which column you are in before the first lot arrives, because the change-control row is the one that bites.

When the brand changes but the factory does not, the part can still change

This is the scenario that catches experienced buyers. You buy private label closures from Brand A. Brand A sources from Factory X. You switch to Brand B for a better price or a shorter lead time. Brand B also sources from Factory X. Same press, same tool, same compound grade. You assume nothing changed. Then your fill line’s torque-to-seal curve shifts.

What changed is the specification Brand B wrote, or did not write. Brand B may have asked for a different durometer to hit a lower price point. It may have accepted a wider dimensional tolerance. It may have changed the washing and drying step, which affects particle counts and residual moisture. The factory did what the customer asked. The customer changed. The part changed with it.

I have seen this play out on a 20 mm finish where the plug diameter moved from 7.60 mm to 7.75 mm between two private label sources running the same tool. Both were “in spec” against their own drawings. The fill line’s stopper placement head, set up for the smaller plug, started seating high on 0.9% of vials, and the downstream seal inspection caught it as a cosmetic defect before it became a container closure integrity failure. The fix was a 40-minute changeover on the placement head and a new incoming inspection limit at 7.65 mm. The lesson was that the brand name on the carton was never the controlling variable. The specification behind it was.

Two field cases where the label lied about the part

Case 1: the coring count that doubled after a label change

A contract fill operation switched from an OEM stopper to a private label equivalent to cut lead time. The stopper drawing matched within tolerance. Within three weeks, the analytical lab reported a rise in visible particles in the reconstituted product, and the coring count on a 10-puncture test went from 2 to 5 particles per vial above 50 µm. The measurement that identified it was a simple puncture sequence on a benchtop capper at the specified needle gauge, followed by microscopic counting. The private label compound had a lower tear resistance at the plug surface. The fix was a return to the OEM compound and a written requirement that any future source submit 10-puncture coring data at the specified gauge before qualification. The dimensional match was never the problem. The recipe was.

Case 2: the seal that passed torque and failed integrity

A small-molecule fill line ran a 13 mm aluminum seal at a crimp height of 6.9 mm and a crimp diameter of 13.25 mm, verified by a calibrated crimp gauge. The private label seal passed the dimensional check on every lot for eight months. Then a stability pull at 40°C/75% RH showed a container closure integrity failure on one timepoint, traced to a seal with a slightly thinner aluminum skirt (0.18 mm versus 0.20 mm) that deformed under the same crimp force. The measurement that found it was a seal-force pull test, not the crimp gauge. The fix was a minimum skirt thickness in the incoming specification and a pull-force acceptance limit of ≥ 25 N. The gauge measured the tool. The pull test measured the part.

Both cases share a shape: the visible dimensions matched, the hidden specification did not, and the failure showed up downstream where it cost more to fix. That is the pattern of private label risk in vial closures. It is manageable, but only if you test the things the label does not show.

A qualification protocol that catches the difference

You do not need to reject private label closures. You need to qualify them against the same physical tests you would run on an OEM part, and you need to hold the result. Here is the checklist I use, with concrete parameters.

• Dimensional stack: measure plug diameter, flange diameter, plug length, and flange thickness on 30 pieces per lot with a calibrated optical comparator or laser micrometer. Accept at the tighter of your drawing or the vendor’s, and record the actual distribution, not just pass/fail.
• Coring: run 10 punctures per stopper with the specified needle gauge on a benchtop capper, count particles above 50 µm, and set an acceptance limit. Anything above 5 per vial deserves a conversation.
• Compression set: 22 hours at 121°C, target under 25% for a butyl stopper. A private label grade that runs 30% will leak at the crimp after autoclave.
• Extractables: 30-day hold at 40°C in the actual product vehicle, screened by analytical testing for unknowns above your internal limit. Do not rely on a Class VI letter alone.
• Seal pull force: ≥ 25 N on a 13 mm aluminum seal after crimping at your production settings.
• Container closure integrity: dye ingress or vacuum decay on 20 filled units per lot at the production crimp setting.

Run this protocol once per source, then re-run the coring and seal-pull tests on every incoming lot. Those two catch the recipe and the metal, which are the two things that move when the label changes.

What actually changes when the brand changes but the factory does not

Let me be direct about the mechanism, because this is the part people get wrong. When Brand A and Brand B both buy from Factory X, the factory does not run two different parts on the same tool unless the customers specified differently. What changes is the specification each brand wrote, the acceptance criteria each brand applies at incoming inspection, and the recourse each brand has when a lot drifts.

If Brand B wrote a looser spec, the factory will happily run to it, because a looser spec is cheaper to hit. If Brand B did no incoming inspection, the factory’s own outgoing check is the only gate, and that gate is set by the factory. If Brand B has no tool ownership, it cannot move the part to a second source when the factory’s press goes down. The factory did not change. The customer’s grip on the factory changed.

This is why I tell procurement teams to treat the brand as a specification holder, not a manufacturer. The question is not “who makes it.” The question is “who wrote the drawing, who owns the steel, and who signs the COA.” Get those three answers and the OEM vs private label vial closures difference resolves into something you can manage. Skip them and you are buying a label.

Where OEM is worth the premium and where private label is the right call

OEM earns its cost when the closure is part of a regulated filing, when the product is sensitive to extractables, or when the fill line runs at a rate where a 0.5% stopper placement rejection costs more than the closure itself. A high-speed line running 300 vials per minute cannot absorb a dimensional drift that a manual line would never notice. In those cases, tool ownership and a brand-held specification are worth the 12 to 20 week lead time.

Private label is the right call for development work, for small clinical batches, for non-regulated research where the closure is not in contact with a filed product, and for operations that can absorb a source change without re-qualifying a line. The HPLC vial market runs largely on private label closures for exactly this reason: the volumes are small, the product is not filed, and the cost of a source change is low.

What you should never do is buy private label and assume OEM behavior. The part may be identical. The control is not.

The decision rule I give every procurement team

If the closure touches a filed product, sits on a line running faster than 150 vials per minute, or carries an extractables limit you cannot afford to miss, buy OEM and require tool ownership, a compound specification, and a brand-issued COA in the contract. If none of those apply, private label is fine, but qualify it against the physical protocol above and re-test coring and seal pull on every lot. The brand on the carton is a proxy for the specification behind it. When the factory stays the same and the brand changes, the specification is the only thing that moved, so make the specification the thing you own. Browse the full vial closures range and the wider chromatography consumables catalog with that rule in hand, and cross-check any vendor claim against published method guidance from EPA SW-846, Agilent, Thermo Fisher, and Restek before you sign.

References & further reading

Related resources from our lab consumables network:

• Vial Closures at vialsclosures.com
• Analytical Testing at testinganalytical.com
• Hplc Vial at vialforhplc.com
• Chromatography Consumables at chromatographyconsumables.com

External references and standards:

• Agilent chromatography consumables and columns
• Thermo Fisher chromatography and sample handling
• U.S. EPA SW-846 test methods for waste and materials
• Restek technical resources for chromatography